Possible applications for combined lenvatinib and pembrolizumab in advanced endometrial carcinoma

Endometrial cancer is one of the most common gynaecological cancers in both United States and Russian Federation, rate continues to rise. Although early-stage endometrial associated with a favourable 5-year survival (96%), this patients distant metastases accounts for only 18%. A combination paclitaxel carboplatin standard first-line therapy advanced, recurrent metastatic carcinoma. Pembrolizumab, monoclonal antibody targeting programmed death-1 receptor, approved solid tumors high microsatellite instability that have progressed aft er previous no alternative treatment options. Lenvatinib an oral multikinase inhibitor blocks vascular endothelial growth factor receptors 1-3, fibroblast 1-4, platelet-derived receptor alpha, RET KIT. Phase II III studies (KEYNOTE-146/ Study111 KEYNOTE-775) on lenvatinib pembrolizumab advanced carcinoma, irrespective MMR MSI status, shown new potential pathology. Th e results obtained, including progression-free overall survival, allow be considered